Literature DB >> 27796542

Reply to letter of Adams and Kwee: Critical considerations on the predictive value of end-of-treatment FDG/PET in lymphoma.

Federico Fallanca1, Pierpaolo Alongi1,2, Elena Incerti1, Luigi Gianolli1, Maria Picchio1, Irfan Kayani3, Jamshed B Bomanji4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 27796542     DOI： 10.1007/s00259-016-3554-7

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN： 1619-7070            Impact factor:   9.236


× No keyword cloud information.
  7 in total

Review 1.  Prognostic value of complete remission status at end-of-treatment FDG-PET in R-CHOP-treated diffuse large B-cell lymphoma: systematic review and meta-analysis.

Authors:  Hugo J A Adams; Rutger A J Nievelstein; Thomas C Kwee
Journal:  Br J Haematol       Date:  2015-04-01       Impact factor: 6.998

2.  Does end-of-treatment FDG-PET provide any additional prognostic value to the pre-treatment NCCN-IPI score?

Authors:  Hugo J A Adams; Thomas C Kwee
Journal:  Br J Haematol       Date:  2016-03-28       Impact factor: 6.998

3.  Diagnostic accuracy of FDG PET/CT for clinical evaluation at the end of treatment of HL and NHL: a comparison of the Deauville Criteria (DC) and the International Harmonization Project Criteria (IHPC).

Authors:  Federico Fallanca; Pierpaolo Alongi; Elena Incerti; Luigi Gianolli; Maria Picchio; Irfan Kayani; Jamshed Bomanji
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-05-07       Impact factor: 9.236

4.  FDG PET/CT Response Assessment Criteria for Patients with Hodgkin's and Non-Hodgkin's Lymphoma at End of Therapy: A Multiparametric Approach.

Authors:  Ur Metser; Ravi Mohan; Vaughan Beckley; Hadas Moshonov; David Hodgson; Grainne Murphy
Journal:  Nucl Med Mol Imaging       Date:  2015-09-29

5.  Follicular lymphoma international prognostic index.

Authors:  Philippe Solal-Céligny; Pascal Roy; Philippe Colombat; Josephine White; Jim O Armitage; Reyes Arranz-Saez; Wing Y Au; Monica Bellei; Pauline Brice; Dolores Caballero; Bertrand Coiffier; Eulogio Conde-Garcia; Chantal Doyen; Massimo Federico; Richard I Fisher; Javier F Garcia-Conde; Cesare Guglielmi; Anton Hagenbeek; Corinne Haïoun; Michael LeBlanc; Andrew T Lister; Armando Lopez-Guillermo; Peter McLaughlin; Noël Milpied; Pierre Morel; Nicolas Mounier; Stephen J Proctor; Ama Rohatiner; Paul Smith; Pierre Soubeyran; Hervé Tilly; Umberto Vitolo; Pier-Luigi Zinzani; Emanuele Zucca; Emili Montserrat
Journal:  Blood       Date:  2004-05-04       Impact factor: 22.113

6.  An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era.

Authors:  Zheng Zhou; Laurie H Sehn; Alfred W Rademaker; Leo I Gordon; Ann S Lacasce; Allison Crosby-Thompson; Ann Vanderplas; Andrew D Zelenetz; Gregory A Abel; Maria A Rodriguez; Auayporn Nademanee; Mark S Kaminski; Myron S Czuczman; Michael Millenson; Joyce Niland; Randy D Gascoyne; Joseph M Connors; Jonathan W Friedberg; Jane N Winter
Journal:  Blood       Date:  2013-11-21       Impact factor: 22.113

7.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease.

Authors:  D Hasenclever; V Diehl
Journal:  N Engl J Med       Date:  1998-11-19       Impact factor: 91.245
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.